Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:

NCT ID: NCT01824680 Suspended - Obesity Clinical Trials

Effect of a Physical Activity Program on the Hormonal Regulation of Food Intake

APHRO
Start date: October 2012
Phase: N/A
Study type: Interventional

The primary purpose of this protocol is to assess the hormonal regulation of satiety by an intense exercise before and after a 3 month physical activity program. Hormones assessed are: leptin, grhélin, Cholecystokinin, Glucagon-Like-Peptid-1 (GLP-1), PYY. It is well known that in overweight adults and children also, an intense physical exercise diminish the food intake relatively to the total energy expenditure and this effect is persistent after a 6 weeks physical activity program. Our hypothesis are: a diminution of food intake after the intense physical exercise and a persistent diminution of food intake after the 3 month physical activity program, an augmentation of levels of GLP-1 and PYY during the intense exercise before and after the physical activity program, a diminution of the level of GLP-1 and leptin before and after the physical activity program

NCT ID: NCT01815216 Suspended - Obesity Clinical Trials

Effect of Gastric Bypass Surgery on Brain Responses

Start date: March 2013
Phase: N/A
Study type: Interventional

After obesity surgery gastric bypass (GBP) patients usually lose more than 50% of its former preponderance in relative short time (~ 2 years). But knowledge of the underlying biological mechanisms of decline in body weight is still inadequate. This project intends to examine patients' background activity in the brain (i.e. "the resting state activity") and brain volume using MRI both before and one year after surgery.

NCT ID: NCT00546455 Suspended - Obesity Clinical Trials

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Start date: December 2007
Phase: Phase 2
Study type: Interventional

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.